• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病与新发肾脏替代治疗对COVID-19患者预后的关联:一项荟萃分析。

The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis.

作者信息

Pranata Raymond, Supriyadi Rudi, Huang Ian, Permana Hikmat, Lim Michael Anthonius, Yonas Emir, Soetedjo Nanny Natalia M, Lukito Antonia Anna

机构信息

Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.

Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia.

出版信息

Clin Med Insights Circ Respir Pulm Med. 2020 Sep 17;14:1179548420959165. doi: 10.1177/1179548420959165. eCollection 2020.

DOI:10.1177/1179548420959165
PMID:32994700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7502996/
Abstract

OBJECTIVE

The aim of the study was to evaluate the association between chronic kidney disease (CKD) and new onset renal replacement therapy (RRT) with the outcome of Coronavirus Disease 2019 (COVID-19) in patients.

METHODOLOGY

A systematic literature search from several databases was performed on studies that assessed CKD, use of RRT, and the outcome of COVID-19. The composite of poor outcome consisted of mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care, and use of mechanical ventilator.

RESULTS

Nineteen studies with a total of 7216 patients were included. CKD was associated with increased composite poor outcome (RR 2.63 [1.33, 5.17],  = .03;  = 51%,  = .01) and its subgroup, consisting of mortality (RR 3.47 [1.36, 8.86],  = .009;  = 14%,  = .32) and severe COVID-19 (RR 2.89 [0.98, 8.46],  = .05;  = 57%,  = .04). RRT was associated with increased composite poor outcome (RR 18.04 [4.44, 73.25],  < .001;  = 87%,  < .001), including mortality (RR 26.02 [5.01, 135.13],  < .001;  = 60%,  = .06), severe COVID-19 (RR 12.95 [1.93, 86.82],  = .008;  = 81%,  < .001), intensive care (IC) (RR 14.22 [1.76, 114.62],  < .01;  = 0%,  < .98), and use of mechanical ventilator (RR 34.39 [4.63, 255.51],  < .0005).

CONCLUSION

CKD and new-onset RRT were associated with poor outcome in patients with COVID-19.

摘要

目的

本研究旨在评估慢性肾脏病(CKD)和新开始的肾脏替代治疗(RRT)与2019冠状病毒病(COVID-19)患者预后之间的关联。

方法

对多个数据库进行系统文献检索,纳入评估CKD、RRT使用情况以及COVID-19预后的研究。不良预后的综合指标包括死亡率、重症COVID-19、急性呼吸窘迫综合征(ARDS)、重症监护需求以及机械通气的使用。

结果

共纳入19项研究,总计7216例患者。CKD与不良预后综合指标增加相关(风险比[RR]2.63[1.33,5.17],P = 0.03;I² = 51%,P = 0.01)及其亚组,包括死亡率(RR 3.47[1.36,8.86],P = 0.009;I² = 14%,P = 0.32)和重症COVID-19(RR 2.89[0.98,8.46],P = 0.05;I² = 57%,P = 0.04)。RRT与不良预后综合指标增加相关(RR 18.04[4.44,73.25],P < 0.001;I² = 87%,P < 0.001),包括死亡率(RR 26.02[5.01,135.13],P < 0.001;I² = 60%,P = 0.06)、重症COVID-19(RR 12.95[1.93,86.82],P = 0.008;I² = 81%,P < 0.001)、重症监护(IC)(RR 14.22[1.76,114.62],P < 0.01;I² = 0%,P < 0.98)以及机械通气的使用(RR 34.39[4.63,255.51],P < 0.0005)。

结论

CKD和新开始的RRT与COVID-19患者的不良预后相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ec/7502996/b4a210dcbd37/10.1177_1179548420959165-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ec/7502996/931f028e083b/10.1177_1179548420959165-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ec/7502996/22f7e60733de/10.1177_1179548420959165-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ec/7502996/b4a210dcbd37/10.1177_1179548420959165-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ec/7502996/931f028e083b/10.1177_1179548420959165-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ec/7502996/22f7e60733de/10.1177_1179548420959165-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ec/7502996/b4a210dcbd37/10.1177_1179548420959165-fig3.jpg

相似文献

1
The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis.慢性肾脏病与新发肾脏替代治疗对COVID-19患者预后的关联:一项荟萃分析。
Clin Med Insights Circ Respir Pulm Med. 2020 Sep 17;14:1179548420959165. doi: 10.1177/1179548420959165. eCollection 2020.
2
Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression.糖尿病与COVID-19肺炎患者的死亡率增加及疾病严重程度相关——一项系统评价、荟萃分析和Meta回归分析
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):395-403. doi: 10.1016/j.dsx.2020.04.018. Epub 2020 Apr 17.
3
Acute Kidney Injury and Renal Replacement Therapy in Critically Ill COVID-19 Patients: Risk Factors and Outcomes: A Single-Center Experience in Brazil.急性肾损伤和危重症 COVID-19 患者的肾脏替代治疗:危险因素和结局:巴西单中心经验。
Blood Purif. 2021;50(4-5):520-530. doi: 10.1159/000513425. Epub 2020 Dec 18.
4
Early versus late initiation of renal replacement therapy in patients with acute kidney injury-a systematic review & meta-analysis of randomized controlled trials.急性肾损伤患者早期与晚期开始肾脏替代治疗——一项随机对照试验的系统评价与荟萃分析
BMC Nephrol. 2017 Feb 28;18(1):78. doi: 10.1186/s12882-017-0486-9.
5
Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study.接受肾脏替代治疗的急性肾损伤重症监护病房患者的长期预后:一项前瞻性队列研究。
Crit Care. 2016 Aug 12;20(1):256. doi: 10.1186/s13054-016-1409-z.
6
COVID-19 and chronic renal disease: clinical characteristics and prognosis.COVID-19 与慢性肾脏病:临床特征与预后。
QJM. 2020 Nov 1;113(11):799-805. doi: 10.1093/qjmed/hcaa258.
7
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.恢复期血浆或高免疫球蛋白用于 COVID-19 患者:一项实时系统评价。
Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub4.
8
Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis.接受肾脏替代治疗的终末期肾病患者中的新冠病毒肺炎:一项系统评价和荟萃分析。
PLoS Negl Trop Dis. 2021 Jun 15;15(6):e0009156. doi: 10.1371/journal.pntd.0009156. eCollection 2021 Jun.
9
Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression.脑血管病和心血管病对 COVID-19 死亡率和严重程度的影响:系统评价、荟萃分析和荟萃回归。
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949. Epub 2020 May 14.
10
Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression.脑血管和心血管疾病对新冠病毒疾病死亡率及严重程度的影响——系统评价、荟萃分析和荟萃回归
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949. Epub 2020 May 14.

引用本文的文献

1
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.新冠病毒仍是威胁吗?免疫功能低下个体持续的医疗负担专家意见综述。
Adv Ther. 2025 Feb;42(2):666-719. doi: 10.1007/s12325-024-03043-0. Epub 2024 Dec 16.
2
COVID-19 outcomes among patients with dementia and age-matched controls who were hospitalized in 21 US health-care systems.21 家美国医疗机构中住院的痴呆症患者与年龄匹配对照者的 COVID-19 结局。
Alzheimers Dement. 2024 Sep;20(9):6395-6406. doi: 10.1002/alz.14136. Epub 2024 Jul 29.
3
Dose response relationship between D-dimer level and mortality in critically ill COVID-19 patients: a retrospective observational study.

本文引用的文献

1
Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19.慢性阻塞性肺疾病和吸烟对 COVID-19 结局的影响。
Int J Tuberc Lung Dis. 2020 Aug 1;24(8):838-843. doi: 10.5588/ijtld.20.0278.
2
Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis.体重指数与 COVID-19 患者结局的关系:剂量-反应荟萃分析。
Diabetes Metab. 2021 Mar;47(2):101178. doi: 10.1016/j.diabet.2020.07.005. Epub 2020 Jul 29.
3
Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis.
D-二聚体水平与危重症 COVID-19 患者死亡率的剂量反应关系:一项回顾性观察研究。
F1000Res. 2023 Jan 10;11:269. doi: 10.12688/f1000research.108972.2. eCollection 2022.
4
Chronic Kidney Disease and COVID-19 Infection: A Case-Control Study.慢性肾脏病与新型冠状病毒肺炎感染:一项病例对照研究
Adv Biomed Res. 2022 Dec 26;11:112. doi: 10.4103/abr.abr_203_21. eCollection 2022.
5
Admission Predictors of Mortality in Hospitalized COVID-19 Patients-A Serbian Cohort Study.住院COVID-19患者死亡率的入院预测因素——一项塞尔维亚队列研究。
J Clin Med. 2022 Oct 17;11(20):6109. doi: 10.3390/jcm11206109.
6
Hypocalcemia: A key biomarker in hospitalized COVID-19 patients.低钙血症:住院 COVID-19 患者的一个关键生物标志物。
Biomed J. 2023 Feb;46(1):93-99. doi: 10.1016/j.bj.2022.08.005. Epub 2022 Aug 28.
7
Risk of Severe SARS-CoV-2 Infection in Patients with Autoimmune Rheumatic Diseases in Qatar: A Cohort Matched Study.卡塔尔自身免疫性风湿病患者感染重症严重急性呼吸综合征冠状病毒2的风险:一项队列匹配研究。
Qatar Med J. 2022 Jun 20;2022(3):24. doi: 10.5339/qmj.2022.24. eCollection 2022.
8
Polycystic ovary syndrome and risks for COVID-19 infection: A comprehensive review : PCOS and COVID-19 relationship.多囊卵巢综合征与 COVID-19 感染风险:全面综述:PCOS 与 COVID-19 的关系。
Rev Endocr Metab Disord. 2022 Apr;23(2):251-264. doi: 10.1007/s11154-022-09715-y. Epub 2022 Feb 26.
9
Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression.血脂异常增加重症 COVID-19 的风险:一项系统评价、荟萃分析和元回归分析
Clin Med Insights Endocrinol Diabetes. 2021 Mar 24;14:1179551421990675. doi: 10.1177/1179551421990675. eCollection 2021.
10
COVID-19 and chronic kidney disease: an updated overview of reviews.COVID-19 与慢性肾脏病:系统评价的更新概述。
J Nephrol. 2022 Jan;35(1):69-85. doi: 10.1007/s40620-021-01206-8. Epub 2022 Jan 11.
以急性肾损伤和新冠病毒病严重程度为重点的多器官功能衰竭:系统评价与荟萃分析
Can J Kidney Health Dis. 2020 Jul 7;7:2054358120938573. doi: 10.1177/2054358120938573. eCollection 2020.
4
Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?2型糖尿病和肥胖症患者感染新冠病毒后的高凝状态:是否需要治疗剂量或更高剂量的抗凝药物进行血栓预防?
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1241-1242. doi: 10.1016/j.dsx.2020.07.015. Epub 2020 Jul 15.
5
Preparedness of Kidney Replacement Therapy in the Critically Ill During COVID-19 Surge.新冠疫情高峰期间危重症患者肾脏替代治疗的准备情况
Kidney Int Rep. 2020 Jun 7;5(7):961-964. doi: 10.1016/j.ekir.2020.05.029. eCollection 2020 Jul.
6
C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.C 反应蛋白、降钙素原、D-二聚体和铁蛋白在严重 2019 冠状病毒病中的meta 分析。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175. doi: 10.1177/1753466620937175.
7
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.肾素血管紧张素系统抑制剂对2019冠状病毒病(COVID-19)患者死亡率的影响:一项系统评价和荟萃分析。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):983-990. doi: 10.1016/j.dsx.2020.06.047. Epub 2020 Jun 27.
8
Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.2019年冠状病毒病(COVID-19)严重患者的淋巴细胞减少症:系统评价与荟萃分析
J Intensive Care. 2020 May 24;8:36. doi: 10.1186/s40560-020-00453-4. eCollection 2020.
9
Cytokine Blood Filtration Responses in COVID-19.细胞因子血液滤过反应与 COVID-19。
Blood Purif. 2021;50(2):141-149. doi: 10.1159/000508278. Epub 2020 May 28.
10
Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?针对危重症 COVID-19 患者的细胞因子风暴综合征,血液净化疗法是否有作用?
Ren Fail. 2020 Nov;42(1):483-488. doi: 10.1080/0886022X.2020.1764369.